Applied DNA Sciences Announces Closing of $8.75 Million Registered Direct Offering

STONY BROOK, NY--(Marketwired - November 25, 2015) - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Twitter: @APDN), a provider of DNA-based supply chain, authentication and product identification solutions, anti-counterfeiting and anti-theft technology, and product genotyping solutions, announced the closing of its registered direct offering pursuant to securities purchase agreements with certain institutional investors of 2,500,000 shares of common stock at a price of $3.49 per share and its concurrent private placement of warrants to purchase 1,250,000 shares of common stock at a price of $.01 per warrant. The warrants have a per share exercise price of $4.30, are exercisable beginning six months from the date hereof and will expire five years from the date on which they become exercisable.

The aggregate gross proceeds to the Company from the registered direct offering and concurrent private placement were $8.75 million before deducting the placement agent's fee and other estimated offering expenses.

The Company intends to use the net proceeds from the registered direct offering and concurrent private placement for general corporate purposes, including working capital, capital expenditures, business development and research and development and acquisitions of new technologies or businesses.

Maxim Group LLC acted as the sole placement agent for the registered direct offering and concurrent private placement.

The shares of common stock described above were offered by Applied DNA Sciences pursuant to a "shelf" registration statement on Form S-3 (File No. 333-202432) filed with the Securities and Exchange Commission (the "SEC"), which was declared effective on March 10, 2015. A prospectus supplement relating to the shares of common stock was filed by the Company with the SEC. Copies of the prospectus supplement, together with the accompanying base prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, [phone].

The warrants and shares of common stock issuable upon exercise of the warrants have not been registered with the SEC and were offered in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Additional information can be found in the Company's filings with the SEC available at www.sec.gov and on the Company's website at www.adnas.com.